Ubiquigent Ltd of the UK has appointed Hozefa Amijee as head of business development to help strengthen the company’s commercial partnerships and further improve its contract research services. Ubiquigent is developing modulators of deubiquitinase enzymes as new therapeutics. Dr Amijee joins from Cellesce Ltd, a biochemical engineering company, where he helped bring the use of organoid models for drug discovery and development. He completed his PhD in biochemistry at the University of Manchester, UK, exploring amyloid aggregation inhibitors as a therapeutic strategy for Alzheimer’s disease.
Ubiquigent announced the appointment on 7 November 2022.
Copyright 2022 Evernow Publishing Ltd